A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 09 Oct 2017 Planned End Date changed from 12 Sep 2019 to 31 Oct 2019.
- 22 Sep 2017 Planned primary completion date changed from 31 Dec 2017 to 21 Jun 2019.
- 10 Jun 2017 Biomarkers information updated